Table 1.

Immunomodulatory drugs used in CCC models.

Reference	Drug	Route/Dose	T. cruzi strain	Main Results
			Animal model
Macambira et al., 2009	Granulocyte colony-stimulating factor	I.P./200 µg/Kg	Colombian	Reduction of myocarditis with increase in the number of apoptotic inflammatory cells and improvement of heart function
			C57BL/6
Vasconcelos et al., 2013	Granulocyte colony-stimulating factor	I.P./200 µg/Kg	Colombian	Reduction of myocarditis and parasite load associated with recruitment of Treg cells
			C57BL/6
Molina-Berríos et al., 2013	Aspirin	Oral/2 or 40 mg/Kg	Dm28c	Reduction of cardiac inflammatory infiltrates and improved of endothelial function
			BALB/c
Pereira et al., 2015	Pentoxifylline	I.P./20 mg/Kg	Colombian	Ameliorate heart injury and dysfunction and downmodulated CD8+ T cells
			C57BL/6 and
			C3H/He (H-2k)
Vilar-Pereira et al., 2016	Pentoxifylline	I.P./20 mg/Kg	Colombian	Reduction myocarditis and fibrosis and improvement electrical alterations
			C57BL/6
Cevey et al., 2017	Fenofibrate+ benzinidazole	Oral/50 to 300 mg/Kg	K-98 and RA	Reduction of myocarditis associated with reversal of the cardiac dysfunction and decrease of pro-inflammatory molecules
			BALB/c
González-Herrera et al., 2017	Simvastatin+ benzinidazole	Oral/5 to 40 mg/Kg	Dm28c	Decrease in cardiac fibrosis and inflammation and on endothelial activation related to 15-epi-lipoxin A4
			BALB/c and Sv/129
Vasconcelos et al., 2017	N,N-dimethylsphingosine	Oral/200 µg/Kg	Colombian	Reduction of myocarditis and parasite load associated with inflammasome pathway activation
			C57BL/6
Meira et al., 2019	BA5 (semi-synthetic derivate from betulinic acid)	Oral/1 or 10 mg/Kg	Colombian	Decrease inflammation and fibrosis in heart associated with IL-10 production and M2 polarization
			C57BL/6

I.P., intraperitoneal route.